- Home
- VNDA vs DSM Comparison
VNDA vs DSM Comparison
Compare VNDA & DSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- DSM
- Stock Information
- Founded
- VNDA 2002
- DSM 1989
- Country
- VNDA United States
- DSM United States
- Employees
- VNDA N/A
- DSM N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- DSM Investment Managers
- Sector
- VNDA Health Care
- DSM Finance
- Exchange
- VNDA Nasdaq
- DSM Nasdaq
- Market Cap
- VNDA 270.0M
- DSM 301.0M
- IPO Year
- VNDA 2006
- DSM N/A
- Fundamental
- Price
- VNDA $4.77
- DSM $5.80
- Analyst Decision
- VNDA Strong Buy
- DSM
- Analyst Count
- VNDA 2
- DSM 0
- Target Price
- VNDA $15.50
- DSM N/A
- AVG Volume (30 Days)
- VNDA 704.2K
- DSM 161.7K
- Earning Date
- VNDA 02-05-2025
- DSM 01-01-0001
- Dividend Yield
- VNDA N/A
- DSM 3.97%
- EPS Growth
- VNDA N/A
- DSM N/A
- EPS
- VNDA N/A
- DSM N/A
- Revenue
- VNDA $190,858,000.00
- DSM N/A
- Revenue This Year
- VNDA $5.60
- DSM N/A
- Revenue Next Year
- VNDA $42.85
- DSM N/A
- P/E Ratio
- VNDA N/A
- DSM N/A
- Revenue Growth
- VNDA N/A
- DSM N/A
- 52 Week Low
- VNDA $3.46
- DSM $4.69
- 52 Week High
- VNDA $6.75
- DSM $6.05
- Technical
- Relative Strength Index (RSI)
- VNDA 42.69
- DSM 27.44
- Support Level
- VNDA $4.49
- DSM $5.76
- Resistance Level
- VNDA $4.81
- DSM $6.18
- Average True Range (ATR)
- VNDA 0.18
- DSM 0.06
- MACD
- VNDA -0.03
- DSM -0.03
- Stochastic Oscillator
- VNDA 25.71
- DSM 8.33
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.